The activation of DR5 also promotes immunogenic cell death in some tumor cells, releasing many damage-associated molecules (DAMPs), including CRT, HMGB1, and ATP, further enhancing the immunogenicity of tumor cells (Teo et al., 2017; Tong et al., 2022). The gene discussed is HMGB1; the disease is neoplasm.